A Phase 1, Single-center, Double-blind, Randomized, Cross-over, Pharmacokinetics, Safety and Tolerability Study of SB204 8% (NVN1000 Gel) and Vehicle Gel
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Nitric oxide (Primary)
- Indications Acne vulgaris
- Focus Pharmacokinetics
- Sponsors Novan Inc
- 27 Apr 2017 Results from this trial will be presented at the 76th Annual Meeting of the Society for Investigative Dermatology 2017, as per a Novan therapeutics media release.
- 10 Jun 2015 Results will be presented at the 23rd World Congress of Dermatology (WCD), as per Novan therapeutics media release.
- 02 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.